Salomon, Levin & Elstein Ltd

Alkylating Agent (platinum analog). Cisplatin 1 mg/ml.
VIALS: 1 x 100 ml, 50 ml. See lit.
Palliative in add. to other modalities
in
tmt. metastat. testic. and ovar. cancer,
advanced bladder cancer.

Folic Acid Analog. Methotrexate 25 mg/ml.
VIAL (sol. for inj.): 25 mg/ ml X 2 ml, 4 ml,
8 ml, 20 ml, 40 ml. Dose must be ajust.
individ. for each pt. accord. to med.
cond. See lit.
Antineopl. Chemother.
Tmt. of gestational choriocarcinoma,
chorioadenoma destruens and
hydatidiform mole. Palliation of ALL. Tmt.
and proph. of menin. leukemia.
Greatest effect has been observed in
palliation of acute lymphoblast.(stemcell)
leukemias in child. In comb. with
other anticancer agents, may be used for
the induc. of remis.,but is most common.
used in the mainten. of induced remis.
May be used alone, or in comb. with other
antineoplastic drugs, in the manag. of
breast canc., epidermoid cancers of the
head and neck, lung cancer (partic.
squamous cell ,small cell types), bladder
cancer and osteogenic cancer. Tmt. of the
advan.stages (III and IV, Peter’s Staging
system) of lymphosarcoma, partic. in
child., and in advanced cases of mycosis
fungoides.
Psoriasis. Indic. only in the sympt. control
of sev. recalcitrant, disabling psoriasis
which is not adeq. responsive to other
forms of therapy, and only when the diag.
has been established, as by biopsy and/or
after dermat. consult. RA:Tmt. of selec.
adul.with sev. RA, only when the diag. has
been well established accord. to rheumat.
standards, with inadeq. response to other
forms of antirheum. ther., includ. full dose
NSAIDs and usually a trial of at least one
or more dis.-modif. antirheum. drugs.
C/I: Pregnancy, lact., pts. in poor state of
nutrition, sev. ren. impair. (crCL <20 ml/
min), sev. liver impair., bone marrow
hypoplasia, leucopenia,
thrombocytopenia, anemia, alcohol
abuse, hypersens. and lung toxic.due to
methotrexate, serious, acute or chronic
infect. such as tuberculosis and HIV,
ulcers of the oral cavity and known
active GI ulcer dis. Concur. vaccin. with
live vaccines.

Domapine Agonist. Apomorphine HCl 10 mg/ml.
AMPS (sol. for inject): 5 x 2 ml, 5 ml. For
S.C. only. Establish pt on domperidone
20 mg 3 x dly for at least 2 days prior
to initiat. ther. Initiat. should be under
specialist vis. Determinat. thresh.
dose: Inject 1 mg (0.1 ml) S.C. dur.
hypokinet. or “off” period. Observe pt
over 30 mins for motor response. If no
response, give 2nd dose 2 mg (0.2 ml)
S.C., observe for 30 mins. Dose can be
incr. with at least a 40 min-interval
until a satisfact. motor response.
Establish. tmt: A single S.C. inject. into
lower abd. or outer thigh at 1st signs
of “off” episode. Observe pt for the
next hr. Precautions on contin. tmt./
cont. infus: See lit.
PEN FOR INJECT: 5 x 3 ml. For S.C. only.
Pts. select. tmt. should be able to
recognize onset of ‘off’ sympts. and
capable of inject. themselves or have a
respons. caregiver to inject them when
req. As per above.
Tmt. disabl. motor flucts. (“on-off”
phenomena) in Parkinson’s dis. which
persist despite individ. titrat. tmt. with
levodopa (with a periph. decarboxylase
inhibit.) and/or other dopamine
agonists.
C/I: Respir. depress., dementia, psychot.
dis., hepat. insuffic. Pts who have an ‘on’
response to levodopa that is marred by
severe dyskines./dyston. Known
hypersens. to apomorphine or any
excip. Child, adolesc. under 18 yrs. of
age.

Analgesic, Antipyretic. Paracetamol 500 mg.
STICK PACK (granules, strawberry/
vanilla flav): 10 x 500 mg. Adults (12
years and over): 1-2 stick packs every
4-6 hrs. Not to exceed 8 packs (4 g
paracetamol) dly. Child: 6-12 yrs: 1
stick pack every 4-6 hrs. Not to exceed
4 packs (2 g paracetamol) dly.
Pain, fever.
C/I: Hypersens.

Analgesic, Antipyretic. Paracetamol 250 mg.
STICK PACK (granules, strawberry-vanilla
flavor): 10 x 250 mg. Child 6-12 yrs: 1-2
stick packs every 4 -6 hrs. Not to exceed 8 packs (2 g paracetamol) dly.
Child: 4-6 yrs: 1 stick pack every 4-6
hrs. Not to exceed 4 packs (1 g
paracetamol) dly.
Pain, fever.
C/I: Hypersens.

Vinca Alkaloid. Vinblastine Sulphate 1 mg/ml.
VIALS: 10 mg. I.V. inject. Initial: Adults:
Single dose 0.1 mg/kg (3.7 mg/m2) 1 x
wkly, follow. by leukocyte count. Child:
Single dose 2.5 mg/m2, follow. by
leukocyte count. Maint. ther., liver, ren.
funct. disords., combinat. ther: See lit.
Tmt. of follow. neoplasms, alone/in
conjunct. with other oncolyt. drugs: Freq.
respons. maligns: General. Hodgkin’s dis.
(stages III and IV, Ann Arbor modific. of Rye
staging system); non-Hodgkin’s
lymphoma, reticulum-cell sarcoma,
lymphosarcoma, mycosis fungoides,
neuroblastoma, Histiocytosis X. Less freq.
respons. maligns: Choriocarcinoma resist.
to other chemotherapeut. agents,
embryonal carcinoma of the testis,
carcinoma of the breast, unrespons. to
approp. endocrine surrg and hormonal
ther.
C/I: Hypersens. to vinblastine or other
vinca-alkaloids, excipients. Leukopen.
not relat. to tumor, severe uncontroll.
infect. Such infects. must first be
controll. with antiseptics/antibiotics bef.
admin. vinblastine, intrathecal admin.
vinblastine.